Sanjay Chandru Keswani - 02 Jun 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Medical Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
02 Jun 2025
Net transactions value
$0
Form type
4
Filing time
04 Jun 2025, 17:37:41 UTC
Previous filing
15 Feb 2022
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Keswani Sanjay Chandru Chief Medical Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 04 Jun 2025 0001818524

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Award $0 +12,846 $0.000000 12,846 02 Jun 2025 Common Stock 12,846 $0.000000 Direct F1, F2
transaction NBIX Stock Option Award $0 +70,101 $0.000000 70,101 02 Jun 2025 Common Stock 70,101 $124.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock upon vesting.
F2 The Restricted Stock Units will vest annually at 25% of the units vesting on each of June 2, 2026, June 2, 2027, June 2, 2028, and June 2, 2029.
F3 Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on June 2, 2026 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.